Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2024 report and make more profitable business decisions.
Leptomeningeal carcinomatosis is a condition involving the infiltration of cancer into the protective layers of the brain, specifically the pia mater and arachnoid mater. Solid tumors, notably breast, lung, melanoma, gastrointestinal, and primary central nervous system tumors, can give rise to leptomeningeal carcinomatosis. Cancer cells may reach the leptomeninges through various routes, such as direct seeding from brain parenchyma, dura mater (not shielded by the blood-brain barrier), bone, endoneurial/perineural invasion, and hematogenous seeding. Symptoms, initially nonspecific, encompass cerebral manifestations like headaches and confusion, posterior fossa indicators such as cranial nerve deficits, vascular complications, spinal cord issues, and inflammatory reactions causing disruptions in CSF flow. Diagnosing leptomeningeal carcinomatosis is challenging due to the low sensitivity of diagnostic tools, necessitating a comprehensive evaluation involving high-quality MRI scans and CSF studies.
The Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) drugs in development market research report provide comprehensive information on the therapeutics under development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AngioChem IncApollomics Inc
Betta Pharmaceuticals Co Ltd
Biodexa Pharmaceuticals PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Codiak BioSciences Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Kadmon Holdings Inc
Kazia Therapeutics Ltd
Memorial Sloan Kettering Cancer Center
Merck & Co Inc
Merck KGaA
Mustang Bio Inc
Nascent Biotech Inc
Plus Therapeutics Inc
Seagen Inc
TYK Medicines Inc
University of Oulu
Table of Contents
Table
Figures
Frequently asked questions